| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/00005373-200109000-00002 |
| P698 | PubMed publication ID | 11535886 |
| P2093 | author name string | E Segal | |
| G Kenet | |||
| M Lynn | |||
| U Martinowitz | |||
| J Ingerslev | |||
| A Lubetsky | |||
| J Luboshitz | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 431-8; discussion 438-9 | |
| P577 | publication date | 2001-09-01 | |
| P1433 | published in | Journal of Trauma | Q15766545 |
| P1476 | title | Recombinant activated factor VII for adjunctive hemorrhage control in trauma | |
| P478 | volume | 51 |
| Q24798640 | 22nd International Symposium on Intensive Care and Emergency Medicine, Brussels, Belgium, 19-22 March 2002 |
| Q55038787 | A Fibrin Cross-linking Polymer Enhances Clot Formation Similar to Factor Concentrates and Tranexamic Acid in an in vitro Model of Coagulopathy. |
| Q36462093 | A critical appraisal of the use of recombinant factor VIIa in acquired bleeding conditions |
| Q37095548 | A review of transfusion risks and optimal management of perioperative bleeding with cardiac surgery |
| Q36469941 | Acidosis and correction of acidosis does not affect rFVIIa function in swine. |
| Q37076545 | Acute resuscitation of the unstable adult trauma patient: bedside diagnosis and therapy |
| Q24797362 | An in vitro evaluation of standard rotational thromboelastography in monitoring of effects of recombinant factor VIIa on coagulopathy induced by hydroxy ethyl starch |
| Q48599230 | An open non-randomized study of recombinant activated factor VII in major postpartum haemorrhage |
| Q47434957 | Analysis and results of the recombinant factor VIIa extended-use registry |
| Q28194591 | Blood substitutes: the future is now |
| Q35578941 | Clinical experiences and current evidence for therapeutic recombinant factor VIIa treatment in nontrauma settings |
| Q35673520 | Coagulation defects in trauma patients: etiology, recognition, and therapy |
| Q36788016 | Coagulopathy: its pathophysiology and treatment in the injured patient |
| Q34120257 | Creation, implementation, and maturation of a massive transfusion protocol for the exsanguinating trauma patient |
| Q76379308 | Damage control surgery |
| Q36839258 | Effect of haemodilution, acidosis, and hypothermia on the activity of recombinant factor VIIa (NovoSeven) |
| Q36154256 | Effects of In vitro hemodilution, hypothermia and rFVIIa addition on coagulation in human blood |
| Q36065825 | Emergent management of pelvic ring injuries: an update |
| Q37996341 | Emerging treatment strategies for trauma-induced coagulopathy |
| Q35788608 | Evaluation of recombinant factor VIIa treatment for massive hemorrhage in patients with multiple traumas |
| Q44737756 | Evolution of US military transfusion support for resuscitation of trauma and hemorrhagic shock |
| Q37691716 | Hemostatic and neuroprotective effects of human recombinant activated factor VII therapy after traumatic brain injury in pigs |
| Q40266094 | Impairment of coagulation by commonly used resuscitation fluids in human volunteers. |
| Q88187780 | Implementation of an off-label recombinant factor VIIa protocol for patients with critical bleeding at an academic medical center |
| Q36543599 | Interventional Algorithms for the Control of Coagulopathic Bleeding in Surgical, Trauma, and Postpartum Settings: Recommendations From the Share Network Group |
| Q36263592 | Intraoperative pediatric blood transfusion therapy: a review of common issues. Part II: transfusion therapy, special considerations, and reduction of allogenic blood transfusions |
| Q41470605 | Intravenous hemostat: nanotechnology to halt bleeding. |
| Q21092902 | Management of bleeding and coagulopathy following major trauma: an updated European guideline |
| Q36349585 | Management of bleeding emergencies: when to use recombinant activated factor VII. |
| Q36296517 | Management of bleeding following major trauma: a European guideline |
| Q33919178 | Management of bleeding following major trauma: an updated European guideline |
| Q37954485 | Massive bleeding: Are we doing our best? |
| Q83968093 | Massive transfusion and coagulopathy: pathophysiology and implications for clinical management |
| Q36284640 | Mechanistic implications for the use and monitoring of recombinant activated factor VII in trauma |
| Q35578975 | Methods for improved hemorrhage control |
| Q38267207 | NovoSeven (recombinant factor VIIa) for the treatment of bleeding episodes and perioperative management in patients with Glanzmann's thrombasthenia |
| Q37279927 | Perioperative use of recombinant factor VII to prevent intraoperative aneurysm rupture in high risk patients: a preliminary safety evaluation |
| Q35544621 | Pharmacokinetics of recombinant activated factor VII in trauma patients with severe bleeding |
| Q33359927 | Pharmacological alternatives to blood transfusion: what is new about? |
| Q36500606 | Pro/con debate: does recombinant factor VIIa have a role to play in the treatment of patients with acute nontraumatic hemorrhage? |
| Q54920142 | Recombinant Factor VIIA. |
| Q37809258 | Recombinant Factor VIIa in Trauma Patients Without Coagulation Disorders |
| Q24801403 | Recombinant activated factor VII (rFVIIa) as salvage treatment for intractable hemorrhage |
| Q59333137 | Recombinant activated factor VII (rFVIIa) in refractory haemorrhage for non-haemophiliacs: an eleven-year single-centre experience |
| Q50746970 | Recombinant activated factor VII (rFVIIa/NovoSeven) in intractable haemorrhage: use of a clinical scoring system to predict outcome. |
| Q36313315 | Recombinant activated factor VII and the anaesthetist. |
| Q45863098 | Recombinant activated factor VII for the rapid correction of coagulopathy in nonhemophilic neurosurgical patients |
| Q33365354 | Recombinant activated factor VII in patients at high risk of bleeding |
| Q33394197 | Recombinant activated factor VII usage in life threatening hemorrhage: a pediatric experience |
| Q36284647 | Recombinant activated factor VIIa and hemostasis in critical care: a focus on trauma |
| Q36372563 | Recombinant coagulation factor VIIa--a novel haemostatic agent in scoliosis surgery? |
| Q35617174 | Recombinant factor VIIa (rFVIIa) and its use in severe bleeding in surgery and trauma: a review |
| Q26822857 | Recombinant factor VIIa as haemostatic therapy in advanced liver disease |
| Q35138036 | Recombinant factor VIIa for control of hemorrhage: early experience in critically ill trauma patients |
| Q36463577 | Recombinant factor VIIa in major abdominal surgery and liver transplantation |
| Q36570888 | Recombinant factor VIIa in paediatric bleeding disorders--a 2006 review |
| Q36492564 | Recombinant factor VIIa in patients with coagulopathy secondary to anticoagulant therapy, cirrhosis, or severe traumatic injury: review of safety profile. |
| Q55543113 | Recombinant factor VIIa in severe trauma: further study needed. |
| Q36412132 | Recombinant factor VIIa: a review on its clinical use. |
| Q36603284 | Recombinant factor VIIa: unregulated continuous use in patients with bleeding and coagulopathy does not alter mortality and outcome |
| Q36263910 | Recombinant factor VIIa: use in fatal post partum hemorrhage - Indian experience case series and review of literature |
| Q42143401 | Recombinant-activated factor VII in patients with uncontrolled bleeding: A retrospective observational analysis |
| Q43055091 | Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding--a European perspective |
| Q36392691 | Safety of rFVIIa in hemodynamically unstable polytrauma patients with traumatic brain injury: post hoc analysis of 30 patients from a prospective, randomized, placebo-controlled, double-blind clinical trial |
| Q45207216 | Single-center experience: use of recombinant factor VIIa for acute life-threatening bleeding in children without congenital hemorrhagic disorder |
| Q80672470 | Successful outcome of DIC and life-threatening bleeding in a toddler with neuroblastoma treated with recombinant activated factor VII |
| Q41820542 | Successful use of recombinant activated factor VII for postoperative associated haemorrhage: a case report |
| Q35742472 | Suicide bombing attacks: update and modifications to the protocol |
| Q64111058 | The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition |
| Q27339343 | The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition |
| Q33368314 | The coagulopathy of massive transfusion. |
| Q38072765 | The early use of fibrinogen, prothrombin complex concentrate, and recombinant-activated factor VIIa in massive bleeding |
| Q41779690 | The effects of commonly used resuscitation fluids on whole blood coagulation |
| Q36349573 | The emerging role of recombinant activated Factor VII (rFVIIa) in the treatment of blunt traumatic haemorrhage |
| Q36262625 | The emerging role of recombinant-activated factor VII in neurocritical care |
| Q39611127 | The influence of coagulation and inflammation research on the improvement of polytrauma care |
| Q35803404 | The next generation in shock resuscitation |
| Q37413124 | The role of recombinant activated Factor VII in major obstetric haemorrhage: the Farnborough experience |
| Q36150578 | The safety and efficacy of the administration of recombinant activated factor VII in major surgery and trauma patients |
| Q33360946 | The use of recombinant activated coagulation factor VII for spine surgery |
| Q51224414 | The use of recombinant activated factor VII in the control of haemorrhage following blunt pelvic trauma. |
| Q78311803 | The use of recombinant factor viia in a jehovah's witness with auto-immune thrombocytopenia and post-splenectomy haemorrhage |
| Q37124610 | Tourniquets: a review of current use with proposals for expanded prehospital use. |
| Q37591799 | Transfusion therapy in hemorrhagic shock |
| Q35185225 | Treating coagulopathy in trauma patients |
| Q79077869 | Treatment of obstetric hemorrhage with recombinant activated factor VII (rFVIIa) |
| Q41856593 | Uncontrolled haemorrhage in pelvic fracturesd---Can the inevitable be avoided? |
| Q33382014 | Understanding the therapeutic action of recombinant factor VIIa in platelet disorders |
| Q37900080 | Update and new developments in the management of the exsanguinating patient |
| Q35563637 | Update on Novo Nordisk's clinical trial programme on NovoSeven® |
| Q35998366 | Use of Activated Recombinant Factor VII in Severe Bleeding - Evidence for Efficacy and Safety in Trauma, Postpartum Hemorrhage, Cardiac Surgery, and Gastrointestinal Bleeding. |
| Q35670771 | Use of recombinant FVIIa for intraperitoneal coagulopathic bleeding in a septic patient |
| Q53860036 | [Damage control laparotomy for haemorragic abdominal trauma. A retrospective multicentric study about 109 cases] |
| Q80852425 | [Management of coagulation after multiple trauma] |
| Q80167797 | [Management of polytrauma] |
| Q80703289 | [Recombinant activated Factor VII] |
| Q81137611 | [Treatment of hemorrhagic shock. New therapy options] |
Search more.